Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBPP) FCF Margin (2016 - 2025)

Historic FCF Margin for Regen BioPharma (RGBPP) over the last 11 years, with Q3 2025 value amounting to 269.52%.

  • Regen BioPharma's FCF Margin rose 796500.0% to 269.52% in Q3 2025 from the same period last year, while for Dec 2025 it was 290.23%, marking a year-over-year decrease of 131000.0%. This contributed to the annual value of 162.15% for FY2025, which is 1555400.0% up from last year.
  • According to the latest figures from Q3 2025, Regen BioPharma's FCF Margin is 269.52%, which was up 796500.0% from 94.77% recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's FCF Margin ranged from a high of 17.71% in Q4 2022 and a low of 1786.88% during Q3 2021
  • For the 5-year period, Regen BioPharma's FCF Margin averaged around 285.73%, with its median value being 187.48% (2022).
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 16432200bps in 2022, then tumbled by -3097500bps in 2024.
  • Over the past 5 years, Regen BioPharma's FCF Margin (Quarter) stood at 472.59% in 2021, then soared by 96bps to 17.71% in 2022, then crashed by -1452bps to 274.84% in 2023, then skyrocketed by 59bps to 112.38% in 2024, then crashed by -140bps to 269.52% in 2025.
  • Its last three reported values are 269.52% in Q3 2025, 94.77% for Q2 2025, and 171.39% during Q1 2025.